Skip to main content

Table 3 Metabolic syndrome prevalence according to ATP III and IDF criteria in the total of patients and by gender and presence of clinical lipodystrophy

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

MS Criteria Total of patients Without CL With CL P
ATP III [n, (%)]     
   Total 180 (52.2%) 71 (51.1%) 109 (52.9%) 0.738
   Men 130 (54.4%) 46 (54.1%) 84 (54.5%) 0.949
   Women 50 (47.2%) 25 (46.3%) 25 (48.1%) 0.854
IDF [n, (%)]     
   Total 149 (43.2%) 64 (46.0%) 85 (41.3%) 0.379
   Men 88 (36.8%) 36 (42.4%) 52 (33.8%) 0.188
   Women 61 (57.5%) 28 (51.9%) 33 (63.5%) 0.227
  1. Note - CL = Clinical lipodystrophy MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass index.